Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma

Launched by INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG) · Nov 26, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a specific type of cancer called transformed splenic marginal zone lymphoma (t-SMZL), which can become more aggressive and is harder to treat. The researchers want to understand the genetic changes that happen in this disease, as there are currently no specific treatments available for patients diagnosed with t-SMZL. By studying the tumor samples from patients, the aim is to learn more about how this condition works and to find better treatment options in the future.

To participate in this trial, you need to be an adult aged 18 or older who has been diagnosed with t-SMZL. Researchers will need access to samples of your tumor tissue from when the disease changed (or transformed) and possibly from when it was first diagnosed. If you join the study, you can expect to provide these samples and some medical information, which will help the doctors and scientists learn more about this complex disease. This study is not yet recruiting participants, but it aims to make a significant impact on how t-SMZL is understood and treated.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults aged 18 years or older, regardless of the gender;
• • 2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease);
• • 3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available;
• • 4. Availability of the baseline and follow-up annotations.
• Exclusion Criteria:
• • None